NEW YORK (GenomeWeb News) – NeoProteomics announced on Tuesday it has been awarded a two-year, $300,000 grant from the National Institutes of Health to develop software for commercial applications.
For its part in the project called DENAMIC, Proteome Sciences will investigate the effects of neurotoxic chemicals on proteins, peptides, and biochemical pathways in cell models and tissue.
Under the terms of an agreement, Protagen's UNIarray platform will be used to retrospectively analyze samples from a Biogen clinical trial in order to find predictive and response biomarkers in relapsing remitting MS.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.